FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Court finds AbbVie used sham litigation to maintain its monopoly on AndroGel but denies FTC request for an injunction; it is the largest monetary award in a litigated FTC antitrust case.

Man Controlling Trade statue in front of the Federal Trade Commission Building

While the Federal Trade Commission lost out on claims AbbVie Inc. engaged in a pay-for-delay deal, it won the overall battle with a court ruling that the company filed sham infringement suits against Teva Pharmaceuticals USA Inc. and Perrigo Co. PLC to block generic competition for its transdermal testosterone replacement therapy AndroGel.

In a June 29 decision, the US District Court for the Eastern District of Pennsylvania ordered AbbVie and its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet